Australia-based Propanc Biopharma announced it secured up to $100 million in funding from Hexstone Capital to build a crypto treasury and accelerate development of its lead cancer therapy PRP, which targets metastatic solid tumors. The private placement, structured as convertible preferred stock, includes an initial $1 million with up to $99 million available over the next 12 months.

Hong Kong-based DDC Enterprise Limited (NYSE: DDC) made its third Bitcoin (BTC) purchase in a week, adding another 100 BTC as it races to build a digital asset treasury targeting 10,000 BTC—roughly $1.2 billion at current prices. The company said it is “accelerating the pace” of acquisitions after laying operational groundwork and partnerships, positioning Bitcoin as a strategic reserve on its balance sheet.

"Buying the Dip" Made Easy...